Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Milner, C.R.
Right arrow Articles by Norman, R.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milner, C.R.
Right arrow Articles by Norman, R.J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Molecular Human Reproduction, Vol. 5, No. 1, 5-9, January 1999
© 1999 European Society of Human Reproduction and Embryology

No association between the –308 polymorphism in the tumour necrosis factor {alpha} (TNF{alpha}) promoter region and polycystic ovaries

C.R. Milner1, J.E. Craig2, N.D. Hussey1 and R.J. Norman1,3

1 Reproductive Medicine Unit, The University of Adelaide, The Queen Elizabeth Hospital, Woodville 5011, South Australia, Australia

The tumour necrosis factor (TNF)2 allele appears to be linked with increased insulin resistance and obesity, conditions often found in overweight patients with polycystic ovary syndrome (PCOS). The significance of TNF{alpha} polymorphism in relation to the clinical and biochemical parameters associated with PCOS was investigated in 122 well-characterized patients with polycystic ovaries (PCO). Of these, 84 had an abnormal menstrual cycle and were classified as having PCOS, while the remaining 38 had a normal menstrual cycle and were classified as having PCO. There were a further 28 individuals without PCO (non-PCO) and 108 individuals whose PCO status was undetermined (reference population). The promoter region of the TNF{alpha} gene was amplified by polymerase chain reaction (PCR), and the presence or absence of the polymorphism at –308 was determined by single-strand conformational polymorphism (SSCP) analysis. The less common TNF allele (TNF2) was found as TNF1/2 or TNF2/2 in 11/38 (29%) of PCO subjects, 25/84 (30%) of PCOS subjects, 7/28 (25%) of non-PCO subjects, and 45/108 (42%) of the reference population. There was no significant difference in the incidence of the TNF2 allele between the groups. The relationship of TNF genotype to clinical and biochemical parameters was examined. In both the PCO group and the PCOS group, the presence of the TNF2 allele was significantly associated with lower glucose values obtained from the glucose tolerance testing (P < 0.05). The TNF genotype was not significantly associated with any clinical or biochemical parameter measured in the PCO, PCOS or non-PCOS groups. Thus, the TNF{alpha} –308 polymorphism does not appear to strongly influence genetic susceptibility to polycystic ovaries.

polycystic ovary syndrome/polymorphism/tumour necrosis factor {alpha}

2 Current address: Walter and Eliza Hall Institute of Medical Research, Melbourne 3000, Australia

3 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol Hum ReprodHome page
M. J. Prodoehl, N. Hatzirodos, H. F. Irving-Rodgers, Z. Z. Zhao, J. N. Painter, T. E. Hickey, M. A. Gibson, W. E. Rainey, B. R. Carr, H. D. Mason, et al.
Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries
Mol. Hum. Reprod., December 1, 2009; 15(12): 829 - 841.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M. Simoni, C.B. Tempfer, B. Destenaves, and B.C.J.M. Fauser
Functional genetic polymorphisms and female reproductive disorders: Part I: polycystic ovary syndrome and ovarian response
Hum. Reprod. Update, September 1, 2008; 14(5): 459 - 484.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
E. Diamanti-Kandarakis and C. Piperi
Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth
Hum. Reprod. Update, November 1, 2005; 11(6): 631 - 643.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Endocr. Rev., April 1, 2005; 26(2): 251 - 282.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. F. Escobar-Morreale, R. M. Calvo, J. Sancho, and J. L. San Millan
TNF-{alpha} and Hyperandrogenism: A Clinical, Biochemical, and Molecular Genetic Study
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3761 - 3767.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. K. Rasmussen, S. A. Urhammer, J. N. Jensen, T. Hansen, K. Borch-Johnsen, and O. Pedersen
The -238 and -308 G->A Polymorphisms of the Tumor Necrosis Factor {alpha} Gene Promotor Are Not Associated with Features of the Insulin Resistance Syndrome or Altered Birth Weight in Danish Caucasians
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1731 - 1734.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.